A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients (VLA-X06)

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 27, 2009

Primary Completion Date

July 28, 2011

Study Completion Date

July 28, 2011

Conditions

Head and Neck Cancer

Interventions

BIOLOGICAL

CVA21

1, 3 or 6 doses of CAVATAK (10\^9 TCID50) at 48 hour intervals.

Trial Locations (3)

St Vincents Hospital, Darlinghurst

Calvary Mater Newcastle Hospital, Newcastle

Monash Medical Centre, Clayton